Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

BERKELEY, US and MAINZ, Germany – September 2, 2025 – Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces today that ColoAlert® has received official registration with the Medicines and Healthcare products Regulatory Agency (MHRA) and is now authorized for marketing in the United Kingdom.

This milestone follows the technology partnership announced earlier this year with EDX Medical Group plc, a leading UK laboratory and represents an important step toward making Mainz Biomed’s DNA-based colorectal cancer (CRC) screening test, ColoAlert, broadly accessible to patients across the country.

Colorectal cancer is the fourth most common cancer in the UK, with approximately 44,000 new cases diagnosed annually. ColoAlert provides a non-invasive approach to CRC screening by detecting DNA biomarkers in stool samples. The test aims to complement the existing Bowel Cancer Screening Program, which currently invites around 4 million people aged 50 to 74 to complete a FIT test annually, by providing an additional, accessible option that could help increase participation.

“With the approval, ColoAlert is now cleared for use across the UK,” said Guido Baechler, CEO of Mainz Biomed. “This regulatory milestone enables our UK laboratory partner to provide a reliable and user-friendly test to a large population, supporting our shared goal of increasing participation in preventive screening and, ultimately, saving more lives.”

The approval of ColoAlert in the UK underscores Mainz Biomed’s commitment to expanding access to innovative diagnostic solutions for early cancer detection. By equipping healthcare providers and patients with an additional tool for colorectal cancer prevention, the Company continues to advance its mission of addressing one of the leading causes of cancer-related mortality worldwide.

About the Author

Dil Bar Irshad

Owner/Editor_In_Chief

Dil Bar Irshad is an Indian journalist, writer, and media entrepreneur from the Marmat area of Doda in Jammu and Kashmir, India. He is best known as the founder and Editor-in-Chief of VoM News ("Voice of Masses"), a digital news portal dedicated to highlighting public grievances and citizen issues.Career Overview• Early Career (2015–2016): He began his reporting career focusing on local public issues and citizen grievances in Jammu and Kashmir. • Regional & National Journalism: Over the years, he served as a District Correspondent for the English newspaper Khalsa Express News (2019–2020) and worked as an Urdu correspondent for Sada e Kohistan. He also reported as a J&K Correspondent for the Millennium Post. • International Reporting: In 2023, he expanded into international journalism, working as an India Correspondent for global agencies like BNN Breaking and later TrimFeed, covering diverse topics ranging from stock market updates to regional and global geopolitical developments. • Media Associations: He is an active member of the All India Media Association.Seen IN: Editor-in-Chief, VoM News India, Jammu and Kashmīr Business and Finance, Crime and Justice, Environment As seen in: VoM News, MSN, MSN India, MSN Singapore, MSN UK, Youth Ki Awaaz, Millennium Post, AgroPages, The California Courier, Hecho En California, Justice News, The Chenab Times, Niguro, Sisnoo